Ophthotech closes recruitment in first Phase III trial of Fovista/ Lucentis combination
Ophthotech has completed patient recruitment in its first Phase III trial of Fovista in combination with anti-VEGF agent Lucentis (ranibizumab) in wet age-related macular degeneration (AMD) programme. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2015 Category: Pharmaceuticals Source Type: news

Residual Edema With Ranibizumab 0.5 mg and 2.0 mg for DMEResidual Edema With Ranibizumab 0.5 mg and 2.0 mg for DME
How effective is a higher dose of ranibizumab in treating persistent DME? The REEF study investigates. Eye (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Ranibizumab for Macular Edema Secondary to RVORanibizumab for Macular Edema Secondary to RVO
A new study compares the efficacy of different doses of ranibizumab for macular edema secondary to RVO -- and whether the addition of non-anti-VEGF treatment provides any additional benefits. BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Repeated Intravitreal Ranibizumab May Increase Intraocular PressureRepeated Intravitreal Ranibizumab May Increase Intraocular Pressure
Repeated intravitreal injections of ranibizumab for diabetic macular edema (DME) may result in sustained elevation of intraocular pressure (IOP), according to results from the Diabetic Retinopathy Clinical Research Network investigators. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 5, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Researcher at Johns Hopkins Helps Lead Discovery on Efficacy and Safety of Eylea, Lucentis and Avastin for Treating Patients with Diabetic Macular Edema - 2/20/15
A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs — Eylea, Avastin and Lucentis — used to treat diabetic macular edema are all effective. (Source: Johns Hopkins Medicine News)
Source: Johns Hopkins Medicine News - February 20, 2015 Category: Research Source Type: news

Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
Lucentis and Avastin perform similarly to Eylea when vision loss is mild, NIH study shows. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 19, 2015 Category: American Health Source Type: news

Johns Hopkins Helps lead discovery on efficacy and safety of 3 drugs for treating DME
(Johns Hopkins Medicine) A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2015 Category: Global & Universal Source Type: news

Anti-VEGF Drugs Boost Vision in Diabetic Eyes (CME/CE)
(MedPage Today) -- Relative effects of intravitreous aflibercept, bevacizumab, and ranibizumab depend on baseline visual acuity. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - February 19, 2015 Category: Urology & Nephrology Source Type: news

Study Compares Drugs for Diabetes-Linked Eye Disease
Eylea has slight advantage over Avastin, Lucentis for people with macular edema, but cost is an issue (Source: WebMD Health)
Source: WebMD Health - February 19, 2015 Category: Consumer Health News Source Type: news

Anti-VEGF Agents Tied to Improved Visual Acuity in Diabetic Macular Edema (FREE)
By Kelly Young Edited by Susan Sadoughi, MD Aflibercept (Eylea), bevacizumab (Avastin), and ranibizumab (Lucentis) all lead to improved vision in patients with diabetic macular edema, although aflibercept may be most effective for those with the worst baseline vision, a New England … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 19, 2015 Category: Primary Care Source Type: news

3 Drugs for an Eye Disease, With Big Price Gaps, Are Found to Be Equals for Many
The three drugs — Eylea, Lucentis and Avastin — are meant to treat a condition known as macular edema, which occurs primarily in patients with diabetes. (Source: NYT Health)
Source: NYT Health - February 19, 2015 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Eyes and Eyesight Roche Holding AG RHHBY Other OTC National Eye Institute Research Eylea (Drug) Regeneron Pharmaceuticals Inc REGN NASDAQ Source Type: news

Study Compares Drugs for Diabetes-Linked Eye Disease
Eylea has slight advantage over Avastin, Lucentis for people with macular edema, but cost is an issue Source: HealthDay Related MedlinePlus Pages: Diabetic Eye Problems, Eye Diseases, Retinal Disorders (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 18, 2015 Category: Consumer Health News Source Type: news

Ranibizumab reverses vision loss caused by diabetes
(University of Southern California - Health Sciences) Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2015 Category: Global & Universal Source Type: news

Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the National Institutes of Health. Language English (Source: News from NEI)
Source: News from NEI - February 16, 2015 Category: Opthalmology Authors: Jason Source Type: news

BRVO: Bevacizumab and Ranibizumab Both EffectiveBRVO: Bevacizumab and Ranibizumab Both Effective
Treatment with anti-VEGF therapy results in rapid improvements in anatomy and function in patients with macular edema caused by branch retinal vein occlusion. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 11, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Pfenex and Hospira to develop Lucentis biosimilar candidate
Clinical-stage biotechnology firm Pfenex has partnered with Hospira to develop and commercialise PF582, Pfenex's biosimilar candidate to Genentech's Lucentis (ranibizumab injection). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 11, 2015 Category: Pharmaceuticals Source Type: news

Lucentis Approved for Diabetic Retinopathy
Title: Lucentis Approved for Diabetic RetinopathyCategory: Health NewsCreated: 2/9/2015 12:00:00 AMLast Editorial Review: 2/10/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - February 10, 2015 Category: Endocrinology Source Type: news

Lucentis Approved for Diabetic Retinopathy
Among diabetics with macular edemaSource: HealthDay Related MedlinePlus Pages: Diabetic Eye Problems, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 9, 2015 Category: Consumer Health News Source Type: news

FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
Roche announced today that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME). DME impacts nearly 750,000 Americans, about 10 percent of people with DR. (Source: Roche Media News)
Source: Roche Media News - February 9, 2015 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
Roche announced today that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME). DME impacts nearly 750,000 Americans, about 10 percent of people with DR. (Source: Roche Investor Update)
Source: Roche Investor Update - February 9, 2015 Category: Pharmaceuticals Source Type: news

Ranibizumab Approved to Treat Diabetic Retinopathy (FREE)
By The Editors The FDA has approved ranibizumab (Lucentis) to treat diabetic retinopathy in patients who have diabetic macular edema.Ranibizumab, previously … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 9, 2015 Category: Primary Care Source Type: news

FDA Clears Ranibizumab for Diabetic Retinopathy With DMEFDA Clears Ranibizumab for Diabetic Retinopathy With DME
Ranibizumab for diabetic retinopathy with DME had breakthrough therapy designation and was reviewed under the agency's priority review program. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 7, 2015 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

FDA approves Lucentis to treat diabetic retinopathy in patients with diabetic macular edema
The U.S. Food and Drug Administration today expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy (DR) in patients with diabetic macular edema (DME). (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 6, 2015 Category: American Health Source Type: news

FDA Okays VEGF Drug for Diabetic Retinopathy
(MedPage Today) -- Lucentis wins an indication in diabetic retinopathy. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 6, 2015 Category: Primary Care Source Type: news

Paid to Promote Eye Drug, and Prescribing It Widely
Half of the 20 doctors who received the most money from Genentech to promote its drug Lucentis in 2013 were among the highest users of the drug in 2012, a federal database shows. (Source: NYT Health)
Source: NYT Health - December 8, 2014 Category: Consumer Health News Authors: By KATIE THOMAS and RACHEL ABRAMS Tags: Medicare Lucentis (Drug) Doctors Roche Holding AG RHHBY Other OTC Macular Degeneration Genentech Inc Avastin (Drug) Source Type: news

NHS: Scandal of the sight saving drug doctors are not allowed to prescribe
Bill Organ’s sight was saved by injections of the drugs Avastin and Lucentis. Both drugs stop the loss of central vision caused by age-related macular degeneration (AMD). (Source: the Mail online | Health)
Source: the Mail online | Health - November 25, 2014 Category: Consumer Health News Source Type: news

Ranibizumab preferred option in myopic CNV
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2014 Category: Drugs & Pharmacology Source Type: news

Regeneron's Eylea Works Better vs Avastin and Lucentis in StudyRegeneron's Eylea Works Better vs Avastin and Lucentis in Study
Regeneron Pharmaceuticals said its drug Eylea (aflibercept) for diabetic macular edema produced significantly greater improvement in visual acuity from baseline to 52 weeks compared with Genentech's Avastin (bevacizumab) and Lucentis (ranibizumab). Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - October 21, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
TARRYTOWN, N.Y., Oct. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net)... Biopharmaceuticals, OphthalmologyRegeneron Pharmaceuticals, EYLEA, aflibercept, Diabetic Macular Edema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2014 Category: Pharmaceuticals Source Type: news

Regeneron's Eylea works better vs Avastin and Lucentis in study
(Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis. (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants Priority Review for Lucentis in diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015. (Source: Roche Investor Update)
Source: Roche Investor Update - October 8, 2014 Category: Pharmaceuticals Source Type: news

Limit Ranibizumab Injections in Macular DegenerationLimit Ranibizumab Injections in Macular Degeneration
Investigators have identified an optimum number of injections of the vascular endothelial growth factor inhibitor for wet age-related macular degeneration in the first year of treatment. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Risk Factors for Geographic Atrophy in the CATT TrialRisk Factors for Geographic Atrophy in the CATT Trial
The CATT results are discussed -- will they help ophthalmologists choose either bevacizumab or ranibizumab? Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 19, 2014 Category: Opthalmology Tags: Ophthalmology Viewpoint Source Type: news

Cheaper alternative to licensed drug for treating eye disease has similar side-effects
(Wiley) Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2014 Category: Global & Universal Source Type: news

Prompt or Delayed Laser Equal in Diabetic Macular EdemaPrompt or Delayed Laser Equal in Diabetic Macular Edema
For patients receiving intravitreal ranibizumab, the timing of laser treatment for diabetic macular edema has little effect on outcome, report researchers. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab vs Laser in Diabetic Macular EdemaRanibizumab vs Laser in Diabetic Macular Edema
Are the differences significant enough to subject patients to the high injection burden required for anti-VEGF treatment? Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 6, 2014 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

More Safety Data Needed for Intravitreal Anti-VEGF AgentsMore Safety Data Needed for Intravitreal Anti-VEGF Agents
Intravitreal use of bevacizumab and ranibizumab does not appear to cause major cardiovascular events or non-ocular bleeding in patients with eye disease, according to a meta-analysis from France. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 5, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Anti-VEGF Improves Quality of Life in Macular DegenerationAnti-VEGF Improves Quality of Life in Macular Degeneration
When patients' vision improved when receiving ranibizumab, their quality of life improved too. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 7, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

France to back Roche cancer drug as cheaper eye treatment
PARIS (Reuters) - The French government, looking to cut healthcare costs, plans to authorize the use of Roche cancer drug Avastin as an alternative eye disease treatment to the much pricier Lucentis, marketed by both Roche and Novartis. (Source: Reuters: Health)
Source: Reuters: Health - July 2, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Switch From Lucentis to Avastin Could Save Medicare $18BSwitch From Lucentis to Avastin Could Save Medicare $18B
Medicare could slash $18 billion in spending over the course of 10 years if physicians treated patients with vision-robbing ailments with bevacizumab instead of ranibizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 17, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Wet AMD drug changed by Italy government
Dr Steven Bradshaw, a drug policy expert and former ophthalmologist, is disappointed at the news of the Italian government’s decision to substitute wet age-related macular degeneration treatment drug, from Lucentis to Roche’s Avastin. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 16, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: Industry News avastin italy Latest News lucentis Steven Bradshaw wet age-related macular degeneration Source Type: news

Study Finds Selecting Cheaper Eye Drug Could Save U.S. Billions
Researchers at the University of Michigan have found that if eye doctors began to prescribe a less expensive eye drug for the wet form of macular degeneration or those who have diabetic macular edema, the U.S. Medicare system could save as much as $18 billion over 10 years. Patients suffering from these two conditions currently have two treatment options: bevacizumab (branded as Avastin), which costs $55 per treatment, or ranibizumab (branded as Lucentis) which costs $2,023 per treatment. Ranibizumab is almost 40 times more expensive than bevacizumab, and the researchers found that the drugs are very similar in terms of ef...
Source: Pharmaceutical Online News - June 9, 2014 Category: Pharmaceuticals Source Type: news

Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab - Bressler NM, Chang TS, Varma R, Suñer I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J.
OBJECTIVES: To determine the impact of ranibizumab on driving status, driving ability perception, and having 20/40 vision or better in patients with choroidal neovascularization resulting from age-related macular degeneration (AMD). DESIGN: Phase III, mult... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - May 27, 2014 Category: Global & Universal Tags: Age: Elder Adults Source Type: news

VEGF Blockade May Slow, but Not Halt, Progression in DME VEGF Blockade May Slow, but Not Halt, Progression in DME
High VEGF, as well as glucotoxicity or other causes, may hasten progression of retinal nonperfusion in diabetic macular edema, suggesting ranibizumab may not prevent retinal capillary closure. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - May 6, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

ASK THE DOCTOR: Will this new drug stop me losing my sight?
Dr Martin Scurr advises a patient who has been treated with Lucentis for an eye condition for years. She has now been prescribed Eylea. (Source: the Mail online | Health)
Source: the Mail online | Health - April 22, 2014 Category: Consumer Health News Source Type: news

Cost of Treatment May Influence Doctors
The American College of Cardiology and the American Heart Association said they would use cost data to rate the value of treatments. (Source: NYT)
Source: NYT - April 18, 2014 Category: American Health Authors: By ANDREW POLLACK Tags: Lucentis (Drug) Gilead Sciences Inc GILD NASDAQ JPMorgan Chase & Company JPM NYSE Drugs (Pharmaceuticals) American Heart Assn American Society of Clinical Oncology Health Insurance and Managed Care Avastin (Drug) American College of Ca Source Type: news

Ranibizumab Holds Visual Line in Real-World StudyRanibizumab Holds Visual Line in Real-World Study
A postmarketing study shows that previously treated and treatment-naïve patients had good visual acuity results at 1 year, with a low incidence of adverse ocular events. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 16, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Visual Outcomes in DME Treated With RanibizumabVisual Outcomes in DME Treated With Ranibizumab
Why do some DME patients continue to have poor vision after ranibizumab therapy? This new study examines the issue. Eye (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 9, 2014 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news